MAPT and Parkinson disease: Aside from the P-tau/α-synuclein ratio, we didn’t identify any additional CSF biomarkers that could effectively separate the PD-I and PD-M at baseline, which was consistent with the mixed symptom severities of the two subtypes at baseline.